Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Daijiro Harada"'
Autor:
Daijiro Harada, Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Yoshinobu Maeda, Katsuyuki Kiura
Publikováno v:
Thoracic Cancer. 14:231-236
Autor:
Shinobu Hosokawa, Eiki Ichihara, Daijiro Harada, Shoichi Kuyama, Koji Inoue, Kenichi Gemba, Hirohisa Ichikawa, Yuka Kato, Naohiro Oda, Isao Oze, Tomoki Tamura, Toshiyuki Kozuki, Takahiro Umeno, Toshio Kubo, Katsuyuki Hotta, Akihiro Bessho, Yoshinobu Maeda, Katsuyuki Kiura
Publikováno v:
International Journal of Clinical Oncology. 27:1139-1144
Autor:
Tomoki Tamura, Kiichiro Ninomiya, Toshio Kubo, Shoichi Kuyama, Sayaka Tachibana, Koji Inoue, Kenichi Chikamori, Kenichiro Kudo, Nobuaki Ochi, Daijiro Harada, Yoshinobu Maeda, Katsuyuki Kiura
Publikováno v:
Thoracic Cancer. 13:453-459
Autor:
Shoichi Kuyama, Kenichiro Kudo, Toshio Kubo, Nobukazu Fujimoto, Akihiro Bessho, Yoshinobu Maeda, Naoyuki Nogami, Makoto Sakugawa, Katsuyuki Hotta, Kadoaki Ohashi, Takashi Ninomiya, Katsuyuki Kiura, Daijiro Harada, Keisuke Aoe, Eiki Ichihara, Daisuke Minami, Keisuke Sugimoto, Nobuaki Ochi, Toshiyuki Kozuki, Nagio Takigawa
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1269-1276
Background In a phase I study, afatinib (30 mg/body daily) plus bevacizumab (15 mg/kg every 3 weeks) was well tolerated and showed favourable outcomes in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer
Autor:
Daijiro Harada, Atsushi Shimonishi, Kazuhiko Saeki, Takashi Ninomiya, Hiromitsu Kanzaki, Kei Nagasaki, China Ogura, Yoko Tsutsui, Kazuhiro Kojin, Yasushi Hamamoto, Toshiyuki Kozuki
Publikováno v:
Asia-Pacific Journal of Clinical Oncology. 19
Durvalumab (Durva) administration after chemoradiation therapy (CRT) in locally advanced non-small-cell lung cancer (NSCLC) is the standard of care, associated with relatively prolonged progression-free (PFS) and overall survival. However, pneumoniti
Autor:
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 643-649 (2021)
Thoracic Cancer
Thoracic Cancer
Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal ep
Autor:
Daisuke Minami, Hiromi Watanabe, Katsuyuki Hotta, Masahiro Tabata, Kenichiro Kudo, Takashi Ninomiya, Toshio Kubo, Eiki Ichihara, Etsuko Murakami, Kammei Rai, Nobuaki Ochi, Kiichiro Ninomiya, Katsuyuki Kiura, Kadoaki Ohashi, Daijiro Harada, Yoshinobu Maeda, Masayuki Yasugi, Keiichi Fujiwara
Publikováno v:
Japanese Journal of Clinical Oncology. 50:1447-1453
Objectives Immune checkpoint inhibitors offer longer survival than chemotherapy in several clinical trials for advanced non-small cell lung cancer. In subset analyses of clinical trials, immune checkpoint inhibitors extended survival in patients aged
Autor:
Kenji Makita, Yasushi Hamamoto, Hiromitsu Kanzaki, Kei Nagasaki, Yoshifumi Sugawara, Takashi Ninomiya, Daijiro Harada, Toshiyuki Kozuki
Publikováno v:
Experimental and therapeutic medicine. 23(5)
The impact of immune checkpoint inhibitors (ICIs) on radiation-induced enterocolitis (RIE) after palliative radiotherapy (PRT) to the bowel has remained to be fully investigated. The aim of the present study was to investigate whether ICIs affect RIE
Autor:
Naoyuki Nogami, Shunta Mori, Yumi Asakura, Daijiro Harada, Kenji Takata, Takayuki Ohno, Satoko Moriki, Toshiyuki Kozuki, Yoshika Takechi
Publikováno v:
Anticancer Research. 39:4987-4993
Background/aim For immune checkpoint inhibitor (ICI)-pretreated patients, docetaxel and ramucirumab (DOC+RAM) combination therapy may be more effective compared to patients not receiving ICI treatment. Patients and methods From June 2013 to July 2018
Autor:
Naoyuki Nogami, Toshio Kubo, Kadoaki Ohashi, Nobuaki Fukamatsu, Katsuyuki Kiura, Toshiyuki Kozuki, Daijiro Harada, Akihiro Bessho, Shinobu Hosokawa, Masayuki Yasugi, Hiroshige Yoshioka, Katsuyuki Hotta, Toshihide Yokoyama, Shoichi Kuyama, Isao Oze, Nagio Takigawa, Kenichiro Kudo, Naoyuki Sone
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation